The purpose of this study is to demonstrate that telotristat etiprate does not differ from placebo in the mean change from Baseline QT interval corrected for heart rate.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
48
1500 mg telotristat etiprate (six 250 mg tablets)
Matching placebo
400 mg moxifloxacin (one 400 mg tablet)
Lexicon Investigational Site
Evansville, Indiana, United States
Mean change from baseline QT interval corrected for heart rate
Time frame: Days 1-3
Number of adverse events
Time frame: 52 days
Plasma concentration of telotristat etiprate
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.